PARPi potentiates with current conventional therapy in MLL leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Cell Cycle"
DOI: 10.1080/15384101.2017.1288325
Abstract: ABSTRACT Acute myeloid leukemias driven by MLL fusion proteins are commonly associated with poor prognosis and refractory treatment. Here, we provide evidence that olaparib can potentiate sensitivity of MLL leukemia cells to conventional chemotherapy and… read more here.
Keywords: cell; mll; dnmt inhibitors; parpi potentiates ... See more keywords